PMID- 9706420
OWN - NLM
STAT- MEDLINE
DCOM- 19981023
LR  - 20220409
IS  - 0392-856X (Print)
IS  - 0392-856X (Linking)
VI  - 16
IP  - 4
DP  - 1998 Jul-Aug
TI  - Increased levels of matrix metalloproteinase-3 in sera from patients with active 
      lupus nephritis.
PG  - 409-15
AB  - OBJECTIVE: To determine the matrix metalloproteinase-3 (MMP-3) levels in sera 
      from patients with systemic lupus erythematosus (SLE) and to analyse the 
      relationships between MMP-3 and clinical and laboratory features. METHODS: Serum 
      MMP-3 levels were measured by an enzyme immunoassay in 124 patients with SLE and 
      237 patients with other systemic rheumatic diseases. RESULTS: The frequencies of 
      patients with high MMP-3 levels were 76% in SLE and 82% in rheumatoid arthritis 
      (RA). The level of MMP-3 in the SLE patients was 193.0 +/- 171.5 ng/ml (mean +/- 
      SD) and was almost equal to the level in the RA patients (259.5 +/- 255.6 ng/ml). 
      The MMP-3 levels were significantly higher in SLE patients who had a history of 
      the following abnormalities: persistent proteinuria, cellular casts, anti-double 
      stranded DNA antibodies, decreased C3, decreased creatinine clearance (p < 
      0.001), circulating immune complex (p < 0.01), malar rash, hypoalbuminemia, or 
      decreased C4 (p < 0.05). The serum MMP-3 level in patients with SLE at admission 
      showed direct correlations with serum uric acid, total cholesterol (p < 0.001), 
      triglyceride, the white blood cell count, and the neutrophil count (p < 0.05), as 
      well as inverse correlations with the total protein (p < 0.01), and IgG (p < 
      0.05). In SLE patients with active renal disease, the median MMP-3 level at 
      admission and that at 6 months after admission were significantly higher than 
      that at 6 months before admission. CONCLUSIONS: The increased level of serum 
      MMP-3 in SLE is closely associated with clinical features relevant to lupus 
      nephritis, suggesting that it plays a role in the pathogenesis of this condition.
FAU - Kotajima, L
AU  - Kotajima L
AD  - Division of Clinical Immunology, Clinical Research Institute, Tokyo, Japan.
FAU - Aotsuka, S
AU  - Aotsuka S
FAU - Fujimani, M
AU  - Fujimani M
FAU - Okawa-Takatsuji, M
AU  - Okawa-Takatsuji M
FAU - Kinoshita, M
AU  - Kinoshita M
FAU - Sumiya, M
AU  - Sumiya M
FAU - Obata, K
AU  - Obata K
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PL  - Italy
TA  - Clin Exp Rheumatol
JT  - Clinical and experimental rheumatology
JID - 8308521
RN  - EC 3.4.24.17 (Matrix Metalloproteinase 3)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Diagnostic Tests, Routine
MH  - Enzyme-Linked Immunosorbent Assay
MH  - Female
MH  - Humans
MH  - Lupus Nephritis/blood/*enzymology/pathology
MH  - Male
MH  - Matrix Metalloproteinase 3/*blood
MH  - Middle Aged
MH  - Regression Analysis
MH  - Retrospective Studies
MH  - Rheumatic Diseases/blood/enzymology/pathology
EDAT- 1998/08/26 00:00
MHDA- 1998/08/26 00:01
CRDT- 1998/08/26 00:00
PHST- 1998/08/26 00:00 [pubmed]
PHST- 1998/08/26 00:01 [medline]
PHST- 1998/08/26 00:00 [entrez]
PST - ppublish
SO  - Clin Exp Rheumatol. 1998 Jul-Aug;16(4):409-15.